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Abstract Increased oxidative stress is known to play a role
in the pathogenesis of atherosclerosis, and polymorphisms in
genes encoding for enzymes involved in modulation of
oxidant stress, such as paraoxonases (PONs), provide a
potentially powerful approach to study the risk of disease
susceptibility. Aim of our study is to investigate the possible
association among PONs polymorphisms, clinical and met-
abolic factors, and atherothrombotic events in an Italian
population. We evaluated in 105 subjects, with or without
atherosclerotic risk factors, the presence of PON1 L55M,
PON1 Q192R, and PON2 S311C genetic variants, as well as
lipid profile, the concentration of aminothiols (blood reduced
glutathione, plasma total glutathione, homocysteine, cys-
teine, cysteinyl glycine), and malondialdehyde as markers of
lipid peroxidation. Clinical, biochemical, and genetic vari-
ables were correlated with a history of atherothrombosis.
Previous atherothrombotic events were found in 42 patients
(40 %): myocardial infarction in 24, stroke or transient
ischemic attack in 18. By multiple logistic regression anal-
ysis, hypertension (OR = 5.538; 95 % CI 2.202–13.902,
P \ 0.001), HDL-cholesterol concentration (OR = 0.947;
95 % CI 0.910–0.985, P = 0.007), and the presence of C
allele in PON2 gene (OR = 3.595; 95 % CI 1.247–10.361,
P = 0.018) were independently associated with athero-
thrombotic events. Our study sheds light on the role of PON2
as a possible cofactor in determining the risk of events
together with the well-known risk markers HDL-cholesterol
and hypertension.
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Introduction
Increased oxidative stress is known to play a role in the
pathogenesis of the atherosclerosis. Oxidation of low
density lipoproteins (LDL) and the subsequent production
of lipid hydroperoxides accelerate the development of
vascular disease by inducing endothelial cell injury,
monocyte activation, smooth muscle cell proliferation, and
foam cell formation. High density lipoprotein (HDL)
concentrations are instead inversely correlated with the
incidence of coronary heart disease [1].
High density lipoproteins exert their anti-atherogenic
effect by different mechanisms: (1) the process of reverse
cholesterol transport from peripheral tissues to liver; (2) the
antioxidant action of paraoxonase (PON), an enzyme
tightly associated with the HDL surface that decreases the
peroxidation of LDL. The PON gene family has three
known members, PON1, PON2, and PON3, located on the
long arm of chromosome 7 between q21.3 and q22.1 in
humans. PON1 is primarily associated with HDL particles
and exerts a cardioprotective function through its hydro-
lyzing effect on LDL-oxidized phospholipids and also on
homocysteine thiolactone [2, 3] which is responsible for
homocysteine pro-atherogenic function [1]. Homocysteine,
like the other metabolically correlated aminothiol cysteine,
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may produce free radical species responsible for the oxi-
dative stress increment, which are known to impair endo-
thelial function.
PON2 is an intracellular protein found in a large variety
of tissues including the arterial wall [4] but it is not asso-
ciated with HDL or LDL. In vitro, PON2 possesses anti-
oxidant properties similar to that of PON1 in preventing
LDL oxidation. The antioxidative and anti-atherogenic
activities of PON2 have been well documented and
recently reviewed [5]; reduced PON2 levels enhanced
atherogenesis in mice [6, 7] and correlated with athero-
sclerosis progression in humans [8]. However, studies
attempting to relate PON2S/C 311 polymorphism to the
risk for CVD and for other diseases have led to equivocal
conclusions [9]. These contradictory data may derive from
ethnic backgrounds; however, they may also be related to
exogenous modulation of PON2 expression by nutrition
and drugs.
Because several evidences support the potential role of
the PON gene family in atherogenesis [10–12], substantial
research has looked for genetic association between PON
variants and atherosclerosis; however, the results have
often been conflicting [13].
Aims of our retrospective study were (a) to investigate the
possible association among PON polymorphisms [PON1
L55M (rs854560) and Q192R (rs662), and PON2 S311C],
clinical and metabolic factors, and a history of athero-
thrombotic events and (b) to verify the association between
PON gene variants and metabolic patterns, assessed by
aminothiols equilibrium, as an index of intracellular and
extracellular redox state, in an Italian population.
Methods
Subjects
One hundred and five subjects with normal (\15 lmol/L)
or moderate–intermediate (C15 and \100 lmol/L) plasma
homocysteine concentrations [14] were selected from
a population referred to our Institution for suspected
hyperhomocysteinemia.
Exclusion criteria were as follows: B19 and C75 years,
previous history of immunologic or neoplastic diseases,
ongoing infection, impaired renal function, surgery or
trauma within the previous month, and vitamin supple-
ments within 2 weeks before the study.
Forty-two subjects had a documented history of ather-
othrombotic events: 24 subjects had had a myocardial
infarction [15] and 18 a stroke [16] or transient ischemic
attack [17]; the remaining 63 subjects had no current
symptoms or clinical/laboratory evidence of arterial vas-
cular disease.
At the time of blood sampling, a complete clinical his-
tory was collected including the assessment of cardiovas-
cular risk factors such as hypertension (systolic and
diastolic blood pressure C140 and 90 mmHg, respectively,
or on antihypertensive drugs [18]), dyslipidemia (LDL C
160 mg/dL or current treatment with lipid-lowering drugs
[19]), diabetes (fasting serum glucose C126 mg/dL in at
least two separate measurements or on antidiabetic drugs
[20]), moderate–intermediate hyperhomocysteinemia and
smoking habits. Patients were taking recommended drugs
for secondary or primary cardiovascular prevention, but
omitted these medications for at least 24 h before sampling.
Written informed consent for genetic and biochemical
analysis was obtained from all the patients.
Sample analysis
After an overnight fast, an antecubital vein was cannulated
and blood was drawn into different pre-chilled Vacutainer
tubes for genetic and biochemical determinations.
Genotyping
Genomic DNA was obtained from peripheral blood sam-
ples by the standard procedure. The analysis of PON1
L55M, Q192R, and the PON2 S311C polymorphisms was
carried out by PCR amplification using a set of primers,
designed as follows:
PON1
L55M
50-GCTCTAGTCCATCAATTTAAAACAAA-30
(upstream)
50-TGGGTATACAGAAAGCCTAAGTGA-30
(downstream)
PON1
Q192R
50-AGACAGTGAGGAATGCCAGTT-30 (upstream)
50-CAGAGAGTTCACATACTTGCCATC-30
(downstream)
PON2
S311C
50-TTCAACAGCATGTCCCCTTA-30 (upstream)
50-AGTGCCTATGAGCAGCTTCC-30 (downstream)
PCR products for PON1 L55M and PON2 S311C were
analyzed by restriction enzyme digestion, using NlaIII and
DdeI, respectively; DHPLC screening and sequence anal-
ysis of the samples with aberrant elution profiles were
performed for PON1 Q192R.
Biochemistry
Immediately after blood collection, sample preparation and
analysis of blood reduced glutathione (GSH) (index of
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GSH concentrations in circulating cells), plasma total
cysteine, homocysteine, and cysteinyl glycine were per-
formed and their concentrations were determined by high
pressure liquid chromatography (HPLC; ProStar, Varian,
Surrey, UK), according to the method previously described
[21]. MDA levels were determined in stored plasma by
HPLC method using a commercial kit (Chromsystems).
Values are expressed as lmol/L.
Total cholesterol, HDL, LDL, and triglycerides were
determined using standard laboratory methods. Values are
expressed as mg/dL.
Statistical analysis
Continuous variables are expressed as median and inter-
quartile range (I, III). Allele distribution of different
genetic variants were tested by v2 or Fisher exact test.
Hardy–Weinberg equilibrium was assessed by calculating
the expected genotype frequencies from the allele in our
study population; deviation from the observed genotype
frequencies was determined by v2. Genotype distributions
in PON1 Q192R and PON2 S311C variants were com-
patible with Hardy–Weinberg equilibrium, but not those in
PON1 L55M polymorphism, which were consequently
dropped from further analysis. The independent relation-
ship of vascular risk factors, biochemical parameters,
genotype combinations of PON1 192 QQ versus QR ? RR
and PON2 311 SS versus SC ? CC with events was tested
by logistic regression analysis; results are expressed as
odds ratio (OR) and their 95 % confidence intervals (CI).
The same analysis was used to compare the genotype
combinations reported above with aminothiol redox equi-
librium in the overall population. Significant variables by
univariable analysis (P \ 0.05) were entered into a step-
wise multivariable logistic regression model to identify
those independently associated with atherothrombotic
events. Diabetes was omitted from the analysis because of
the scant number of subjects.
Statistical analysis was carried out using the Statistical
Package for the Social Sciences (SPSS Inc., Chicago, Ill.,
U.S.) release 17.0 for Windows.
Results
Comparison of clinical, metabolic, and genetic factors
with atherothrombotic events
We classified enrolled subjects in two groups, according to
the absence (AE- group, n = 63) or presence (AE?
group, n = 42) of a history of atherothrombotic events.
The distribution of PON1 and PON2 polymorphisms was
assessed in AE? and AE- groups. The allele frequency of
PON1 Q192R variant was similar in both groups, while the
allelic distribution of PON2 S311C significantly differed in
AE? and AE- groups (Table 1).
Baseline clinical, biochemical, and genetic characteris-
tics of the enrolled subjects are reported in Table 2.
Moderate/intermediate hyperhomocysteinemia (concentra-
tion range 15.4–74.8 lmol/L) was present in 45 % of
enrolled subjects. Drug treatment was differently distrib-
uted between AE? and AE- groups, in accordance with
guideline recommendations for secondary and primary
cardiovascular prevention: AE? subjects took in a higher
proportion of renin-angiotensin system inhibitors, statins,
antiplatelet agents, and b-blockers than AE- subjects
(Table 3). Because of this clinically consistent treatment
bias, we did not include therapy variables in the logistic
regression analysis.
By univariable logistic regression analysis, male gender,
age, hypertension, dyslipidemia, total plasma GSH, and
PON2 311C alleles were positively associated with ather-
othrombotic events, while HDL was inversely associated
with AE?.
In the multivariable logistic regression model, only
hypertension (P \ 0.001, OR = 5.538; 95 % CI 2.202–
13.902), HDL (P = 0.007, OR = 0.947; 95 % CI 0.910–
0.985), and the presence of C allele in PON2 gene
(P = 0.02, OR = 3.595; 95 % CI 1.247–10.361) were
independently associated with previous atherothrombotic
events.
Table 1 Genotype distribution and allelic frequencies of PONs
polymorphisms in the study population
Total
(n = 105)
AE- group
(n = 63)
AE? group
(n = 42)
P
PON1: Q192R
Genotypes
Q/Q 57 (54 %) 33 (52.4 %) 24 (57.1 %)
Q/R 40 (38 %) 26 (41.3 %) 14 (33.3 %)
R/R 8 (8 %) 4 (6.3 %) 4 (9.5 %)
Alleles 1.00
Q 0.733 0.730 0.738
R 0.267 0.270 0.262
PON2: S311C
Genotypes
S/S 74 (70 %) 50 (79.4 %) 24 (57.1 %)
S/C 26 (25 %) 10 (15.9 %) 16 (38.1 %)
C/C 5 (5 %) 3 (4.8 %) 2 (4.8 %)
Alleles 0.04
S 0.829 0.873 0.762
C 0.171 0.127 0.238
AE? with atherothrombotic event, AE- without atherothrombotic
events, PON paraoxonase
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Comparison between genetic variants and aminothiols
status
A logistic regression analysis was also used to compare
genotype combinations of PON1 192 QQ versus QR ? RR
and PON2 311 SS versus SC ? CC with the aminothiols
pattern in the overall population.
No association was found in these comparisons.
Discussion
Susceptibility to cardiovascular disease is increasingly
demonstrated to be the result of an interaction among
lifestyle, environment, and genetic factors. Our study found
that PON2 S311C polymorphism, hypertension, and low
levels of HDL are independently associated with athero-
thrombotic disease in an Italian subpopulation.
Several authors link oxidative stress to cardiovascular
events [22] which are usually triggered by arterial throm-
bosis. Overproduction of reactive oxygen species (ROS)
that outstrips antioxidant defenses can lead to endothelial
cell injury, thus contributing to the pathophysiology of
atherogenesis. Polymorphisms in genes encoding enzymes
involved in oxidative stress modulation provide a poten-
tially powerful approach to study disease susceptibility
[23], and PON genes represent good candidates.
Although PONs were initially identified for their ability
to metabolize pesticide-derived organophosphates like
paraoxon, they have received increasing attention in the
field of cardiovascular prevention for their presumed anti-
oxidant and anti-inflammatory role.
PON1 genetic variants are known to have major influ-
ence on the serum concentration as well as on the catalytic
activity of the enzyme. Indeed, the 192RR genotype is
associated with the greatest hydrolytic activity against
paraoxon; whereas, the 192QQ possesses the highest pro-
tective capacity against LDL oxidation [24]. In the coding
region of PON2, the S311C polymorphism has been
associated with variations in lipoprotein metabolism and
plasma lipoprotein concentration [11].
Table 2 Clinical, biochemical and genetic characteristic of the study population
Characteristic Total (n = 105) AE- group (n = 63) AE? group (n = 42) P OR 95 % CI
Age, years 50 [38, 60] 45 [31, 56] 53 [44, 63] 0.01 1.040 1.009–1.071
Male sex, n (%) 75 (71) 39 (62) 36 (86) 0.01 3.692 1.355–10.064
Hypertension, n (%) 42 (40) 15 (24) 27 (64) \0.001 5.760 2.445–13.571
Hyperhomocysteinemia, n (%) 57 (45) 30 (48) 17 (41) 0.47 0.748 0.339–1.648
Smoking habit, n (%) 44 (42) 26 (41) 18 (43) 0.87 1.067 0.484–2.353
Dyslipidemia, n (%) 45 (43) 21 (33) 24 (57) 0.02 2.667 1.192–5.964
PON1 192 QR ? RR, n (%) 48 (46) 30 (48) 18 (43) 0.63 0.825 0.376–1.811
PON2 311 SC ? CC, n (%) 31 (30) 13 (21) 18 (43) 0.02 2.885 1.216–6.841
b-r-GSH, lmol/L 556 [388, 788] 599 [387, 789] 522 [355, 762] 0.35 0.999 0.998–1.001
p-t-GSH, lmol/L 5.47 [4.03, 7.35] 6.1 [4.8, 7.8] 4.6 [3.4, 5.9] 0.006 0.778 0.651–0.929
p-t-Cys, lmol/L 249 [198, 303] 252 [183, 302] 243 [207, 312] 0.71 1.001 0.996–1.006
p-t-Hcy, lmol/L 14.1 [8.9, 24.0] 14.1 [8.7, 24.2] 13.9 [9.5, 22.1] 0.50 0.990 0.960–1.020
p-t-CysGly, lmol/L 32 [23, 47] 31 [23, 48] 33 [23, 45] 0.27 0.988 0.968–1.009
MDA, lmol/L 0.75 [0.46, 1.45] 0.67 [0.38, 1.19] 0.94 [0.59, 1.54] 0.23 1.429 0.769–2.564
Total cholesterol, mg/dL 188 [158, 218] 189 [160, 222] 182 [152, 210] 0.32 0.995 0.986–1.005
HDL-cholesterol, mg/dL 52 [43, 62] 54 [45, 63] 46 [38, 59] 0.008 0.954 0.922–0.988
LDL-cholesterol, mg/dL 108 [88, 140] 111 [88, 147] 106 [83, 137] 0.62 0.997 0.987–1.008
Triglycerides, mg/dL 100 [70, 157] 95 [68, 144] 108 [79, 195] 0.35 1.002 0.997–1.008
Data are expressed as median [I, III] or number (%)
OR odds ratio, CI confidence interval, PON paraoxonase, b blood, p plasma, r reduced, t total, GSH glutathione, Cys cysteine, Hcy homocysteine,
CysGly cysteinyl glycine, MDA malondialdehyde, HDL high density lipoproteins, LDL low density lipoproteins
Table 3 Drug treatment
Total
(n = 105)
AE-
(n = 63)
AE?
(n = 42)
P
ACE-inhibitors/
ARBs
23 (22 %) 6 (10 %) 17 (41 %) \0.001
Beta-blockers 15 (15 %) 3 (5 %) 12 (29 %) 0.001
Antiplatelet agents 45 (44 %) 12 (19 %) 33 (81 %) \0.001
Statins 22 (21 %) 7 (11 %) 15 (37 %) 0.003
Calcium channel
blockers
14 (14 %) 7 (11 %) 7 (17 %) 0.56
AE? with atherothrombotic event, AE- without atherothrombotic
events
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PON2 is constitutively expressed in both primary and
immortalized human endothelial cells and human aortic
smooth muscle cells. This enzyme, absent in plasma, exerts
antioxidant properties by reducing the production of
intracellular hydroperoxides and/or cell-mediated LDL
oxidation and inhibits the ability of oxidized LDL to induce
monocyte chemotactic activity in human aortic endothelial
cells. In vitro studies showed that PON2 overexpression
lowers the intracellular oxidative state of cells treated
with hydrogen peroxide or oxidized L-a-1-palmitoyl-2-
arachi-donyl-sn-glycero-3-phosphorylcholine [4]. More-
over, recent studies suggest that PON2, in association with
PON3, was found in subcellular mitochondrial fractions,
which prevents the ubisemiquinone mediated-mitochon-
drial superoxide generation [5, 7]. As LDL oxidation is
believed to be a major initiator of atherosclerotic lesions,
PON2 expression in arterial cells is likely to play a key role
in the body resistance to vascular disease. In our popula-
tion, the presence of C allele in the PON2 gene was
associated with previous vascular events. The PON2 311C
allele showed a higher prevalence among Chinese Han
patients [25], and was related to an increased risk of
myocardial infarction in Italian [12] and Spanish popula-
tions [26]. Conversely, some studies indicated that PON2
311S allele frequency was significantly higher in coronary
artery disease patients, both in Asian–Indian, than in Tai-
wan subjects [27].
However, the activity of PON2 enzyme is not as well
characterized as that of PON1, and several studies showed
that PON2 311C allele is linked to decreased lactonase [28]
and LDL antioxidant activities [4].
We were not able to find any significant association
between Q192R PON1 genetic variants and atherothrom-
botic events. Our results agree with other studies that failed
to demonstrate a relation between PON1 gene variants and
coronary artery disease risk [29, 30]. These conflicting
results may arise from differences in the ethnic back-
ground, as well as in the selection criteria for cases and
controls, and from heterogeneity of the clinical endpoints
considered. Moreover, the lack of PON1 association with
coronary artery disease may be due to the less specific
action of this protein. In fact, PON1 is a plasma antioxidant
enzyme, highly expressed in the liver where it is associated
with the HDL particle. PON1, however, does not act in
vascular endothelial cells where the early atherogenetic
process starts after LDL accumulation and oxidation.
Conversely, PON2 appears to be ubiquitously expressed in
most human tissues, and particularly, in the arterial wall
where this protein may be considered an additional element
of antioxidant and anti-atherosclerotic vascular defense.
The protective role of HDL, as well as the negative
contribution of hypertension, have been extensively studied
and confirmed so far. In agreement with the literature
[1, 31], we also found a strong independent relationship
among low HDL levels, hypertension, and atherothrom-
botic events.
Study limitations
The relatively small sample size of our population repre-
sents a limit of our study; however, all data were in
agreement with the distribution of PON polymorphisms in
a large control population [32]. Furthermore, we have
enrolled subjects who were clinically and biochemically
well-defined.
We did not measure the enzymatic activity of PONs, but
we have studied gene variations known to be associated
with an altered antioxidant property.
Conclusions
Our study adds further knowledge on the role of PON2 as a
possible cofactor in determining the risk of atherothrom-
botic events, through its cell-specific antioxidant property
in the first step of lipid oxidation. Indeed, cell-associated
PON2 could act, in concert with the serum-associated
enzymes PON1, to decrease vascular ROS and contrast the
development of atherosclerosis.
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